U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H28O7
Molecular Weight 416.4642
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LICOGLIFLOZIN

SMILES

CCC1=C(CC2=CC=C3OCCOC3=C2)C=C(C=C1)[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O

InChI

InChIKey=XFJAMQQAAMJFGB-ZQGJOIPISA-N
InChI=1S/C23H28O7/c1-2-14-4-5-15(23-22(27)21(26)20(25)19(12-24)30-23)11-16(14)9-13-3-6-17-18(10-13)29-8-7-28-17/h3-6,10-11,19-27H,2,7-9,12H2,1H3/t19-,20-,21+,22-,23+/m1/s1

HIDE SMILES / InChI

Molecular Formula C23H28O7
Molecular Weight 416.4642
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

LIK-066 (licogliflozin) is an inhibitor of the sodium-dependent glucose co-transporter (sodium-glucose transporter; sodium-glucose transport protein; sodium-glucose linked transporter; SGLT) family members 1 and 2 (SGLT1/2) with antihyperglycemic activity. By binding to and blocking SGLT1/2, licogliflozin suppresses the reabsorption of glucose in the proximal tubule within the kidneys and enhances urinary excretion of glucose. This normalizes blood glucose levels. LIK-066 is in phase II clinical trials by Novartis for the treatment of type 2 diabetes. Licogliflozin treatment (1-84 days) leads to significant weight loss and favorable changes in a variety of metabolic parameters and incretin hormones. Dual inhibition of SGLT1/2 with licogliflozin in the gut and kidneys is an attractive strategy for treating obesity and diabetes.

Approval Year

PubMed

PubMed

TitleDatePubMed
The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes.
2019 Jun
Patents

Patents

Sample Use Guides

150 mg q.d. for 12 weeks
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:39:45 GMT 2023
Edited
by admin
on Sat Dec 16 09:39:45 GMT 2023
Record UNII
57J06X6EI0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LICOGLIFLOZIN
INN  
Official Name English
D-GLUCITOL, 1,5-ANHYDRO-1-C-(3-((2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)METHYL)-4-ETHYLPHENYL)-, (1S)-
Systematic Name English
licogliflozin [INN]
Common Name English
Licogliflozin [WHO-DD]
Common Name English
LIK-066
Code English
LIK066
Code English
Classification Tree Code System Code
NCI_THESAURUS C98083
Created by admin on Sat Dec 16 09:39:45 GMT 2023 , Edited by admin on Sat Dec 16 09:39:45 GMT 2023
Code System Code Type Description
INN
10703
Created by admin on Sat Dec 16 09:39:45 GMT 2023 , Edited by admin on Sat Dec 16 09:39:45 GMT 2023
PRIMARY
FDA UNII
57J06X6EI0
Created by admin on Sat Dec 16 09:39:45 GMT 2023 , Edited by admin on Sat Dec 16 09:39:45 GMT 2023
PRIMARY
NCI_THESAURUS
C150375
Created by admin on Sat Dec 16 09:39:45 GMT 2023 , Edited by admin on Sat Dec 16 09:39:45 GMT 2023
PRIMARY
DRUG BANK
DB15048
Created by admin on Sat Dec 16 09:39:45 GMT 2023 , Edited by admin on Sat Dec 16 09:39:45 GMT 2023
PRIMARY
CAS
1291094-73-9
Created by admin on Sat Dec 16 09:39:45 GMT 2023 , Edited by admin on Sat Dec 16 09:39:45 GMT 2023
PRIMARY
PUBCHEM
52913524
Created by admin on Sat Dec 16 09:39:45 GMT 2023 , Edited by admin on Sat Dec 16 09:39:45 GMT 2023
PRIMARY
SMS_ID
100000181115
Created by admin on Sat Dec 16 09:39:45 GMT 2023 , Edited by admin on Sat Dec 16 09:39:45 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY